175 related articles for article (PubMed ID: 26220094)
1. Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer.
Shimizu T; Nakagawa Y; Takahashi N; Hashimoto S
Clin Transl Oncol; 2016 Jan; 18(1):107-12. PubMed ID: 26220094
[TBL] [Abstract][Full Text] [Related]
2. Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer.
Chamizo C; Zazo S; Dómine M; Cristóbal I; García-Foncillas J; Rojo F; Madoz-Gúrpide J
BMC Pulm Med; 2015 Oct; 15():132. PubMed ID: 26502926
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma.
Kasai D; Ozasa H; Oguri T; Miyazaki M; Uemura T; Takakuwa O; Kunii E; Ohkubo H; Maeno K; Niimi A
Anticancer Res; 2013 May; 33(5):1935-40. PubMed ID: 23645741
[TBL] [Abstract][Full Text] [Related]
4. Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.
Shimizu T; Nakanishi Y; Nakagawa Y; Tsujino I; Takahashi N; Nemoto N; Hashimoto S
Anticancer Res; 2012 Oct; 32(10):4589-96. PubMed ID: 23060591
[TBL] [Abstract][Full Text] [Related]
5. Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients.
Agulló-Ortuño MT; García-Ruiz I; Díaz-García CV; Enguita AB; Pardo-Marqués V; Prieto-García E; Ponce S; Iglesias L; Zugazagoitia J; López-Martín JA; Paz-Ares L; Nuñez JA
Cancer Chemother Pharmacol; 2020 Mar; 85(3):525-535. PubMed ID: 31832811
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
Cardona AF; Rojas L; Wills B; Arrieta O; Carranza H; Vargas C; Otero J; Cuello M; Corrales L; Martín C; Ortiz C; Franco S; Rosell R;
PLoS One; 2016; 11(5):e0154293. PubMed ID: 27191954
[TBL] [Abstract][Full Text] [Related]
7. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.
Nicolson MC; Fennell DA; Ferry D; O'Byrne K; Shah R; Potter V; Skailes G; Upadhyay S; Taylor P; André V; Nguyen TS; Myrand SP; Visseren-Grul C; Das M; Kerr KM
J Thorac Oncol; 2013 Jul; 8(7):930-9. PubMed ID: 23722170
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902.
Kanazawa K; Yokouchi H; Wang X; Ishida T; Fujita Y; Fujiuchi S; Harada T; Harada M; Takamura K; Oizumi S; Kinoshita I; Katsuura Y; Honjo O; Kojima T; Dosaka-Akita H; Isobe H; Munakata M; Nishimura M;
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1149-57. PubMed ID: 25294632
[TBL] [Abstract][Full Text] [Related]
9. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.
Chen CY; Chang YL; Shih JY; Lin JW; Chen KY; Yang CH; Yu CJ; Yang PC
Lung Cancer; 2011 Oct; 74(1):132-8. PubMed ID: 21367480
[TBL] [Abstract][Full Text] [Related]
10. Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker.
Ramlau R; Thomas M; Novello S; Plummer R; Reck M; Kaneko T; Lau MR; Margetts J; Lunec J; Nutt J; Scagliotti GV
Clin Lung Cancer; 2015 Sep; 16(5):348-57. PubMed ID: 25700774
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
[TBL] [Abstract][Full Text] [Related]
12. Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis.
Wang T; Chuan Pan C; Rui Yu J; Long Y; Hong Cai X; De Yin X; Qiong Hao L; Li Luo L
PLoS One; 2013; 8(9):e74284. PubMed ID: 24040222
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
[TBL] [Abstract][Full Text] [Related]
14. The role of thymidylate synthase in non-small cell lung cancer treated with pemetrexed continuation maintenance therapy.
Yang M; Fan WF; Pu XL; Meng LJ; Wang J
J Chemother; 2017 Apr; 29(2):106-112. PubMed ID: 27866454
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement.
Zhang L; Jiang T; Zhao C; Li W; Li X; Zhao S; Liu X; Jia Y; Yang H; Ren S; Zhou C
Oncotarget; 2016 Nov; 7(46):75145-75154. PubMed ID: 27738334
[TBL] [Abstract][Full Text] [Related]
16. Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).
Kotoula V; Krikelis D; Karavasilis V; Koletsa T; Eleftheraki AG; Televantou D; Christodoulou C; Dimoudis S; Korantzis I; Pectasides D; Syrigos KN; Kosmidis PA; Fountzilas G
BMC Cancer; 2012 Aug; 12():342. PubMed ID: 22866924
[TBL] [Abstract][Full Text] [Related]
17. Association between gene expression profiles and clinical outcome of pemetrexed-based treatment in patients with advanced non-squamous non-small cell lung cancer: exploratory results from a phase II study.
Fennell DA; Myrand SP; Nguyen TS; Ferry D; Kerr KM; Maxwell P; Moore SD; Visseren-Grul C; Das M; Nicolson MC
PLoS One; 2014; 9(9):e107455. PubMed ID: 25250715
[TBL] [Abstract][Full Text] [Related]
18. Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis.
Liu Y; Yin TJ; Zhou R; Zhou S; Fan L; Zhang RG
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1125-32. PubMed ID: 24067998
[TBL] [Abstract][Full Text] [Related]
19. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR
J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958
[TBL] [Abstract][Full Text] [Related]
20. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.
Hirsch FR; Herbst RS; Olsen C; Chansky K; Crowley J; Kelly K; Franklin WA; Bunn PA; Varella-Garcia M; Gandara DR
J Clin Oncol; 2008 Jul; 26(20):3351-7. PubMed ID: 18612151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
